OSLO - 16th ofJanuary 2024 : Reference is made to SoftOx (the Company) press release of 11th ofJanuary 2024 where the Company announced on-going work to restructure the financial situation. The Company is in process of reaching an agreement with the lenders in theNOK 40 million convertible loan with due date of 15th ofJanuary 2024 to prolong the due date until 1st ofApril 2024 on certain conditions, proposed by one of the largest holders in the loan. So far, 88% of the holders of the convertible loan have accepted the proposal. The company will revert with further information after all lenders have given their feedback.SoftOx Solutions AS Mail: ir@soft-ox.com Phone: (+47) 977 50 071 (Chairman of the Board Geir Almås) AboutSoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is aMedtech and clinical-stage pharmaceutical company based inOslo, Norway , with the goal of reducing the spread of infection and emergence of antimicrobial resistance. For more information on SoftOx, visit www.soft-ox.com
Click here for more information
© Oslo Bors ASA, source